Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John E Kraus

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
The Journal of Neuropsychiatry and Clinical Neurosciences|March 5, 2005
Clozapine reduces violent behavior in heterogeneous diagnostic groupsJohn E Kraus, Brian B Sheitman
Psychiatric Services (Washington, D.C.)|February 6, 2004
Characteristics of violent behavior in a large state psychiatric hospitalJohn E Kraus, Brian B Sheitman
The Journal of Clinical Psychiatry|August 5, 2004
Neurosyphilis in newly admitted psychiatric patients: three case reportsSusan Saik, John E Kraus, Alex McDonald, et al.
The Journal of Clinical Psychiatry|January 13, 2006
Olanzapine versus risperidone in newly admitted acutely ill psychotic patientsJohn E Kraus, Brian B Sheitman, Alan Cook, et al.
Administration and Policy in Mental Health|December 7, 2007
Managing treatment resistant violent adolescents: a step forward by substituting seclusion for mechanical restraint?Thomas C Larson, Brian B Sheitman, John E Kraus, et al.
Journal of Clinical Psychopharmacology|October 2, 2003
Effects of topiramate on aggressive, self-injurious, and disruptive/destructive behaviors in the intellectually disabled: an open-label retrospective studyDavid S Janowsky, John E Kraus, Jarrett Barnhill, et al.
The Journal of Clinical Psychiatry|March 4, 2011
Meta-analysis of efficacy and treatment-emergent suicidality in adults by psychiatric indication and age subgroup following initiation of paroxetine therapy: a complete set of randomized placebo-controlled trialsDavid J Carpenter, Regan Fong, John E Kraus, et al.
Journal of the American Academy of Dermatology|January 8, 2019
Phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasisKevin Robbins, Robert Bissonnette, Tomoko Maeda-Chubachi, et al.
CNS Drugs|October 9, 2008
Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disordersDavid V Sheehan, Matthew S Keene, Michael Eaddy, et al.
Journal of the American Academy of Dermatology|December 18, 2018
A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitisJohnny Peppers, Amy S Paller, Tomoko Maeda-Chubachi, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
The Journal of Neuropsychiatry and Clinical Neurosciences|March 5, 2005
Clozapine reduces violent behavior in heterogeneous diagnostic groupsJohn E Kraus, Brian B Sheitman
Psychiatric Services (Washington, D.C.)|February 6, 2004
Characteristics of violent behavior in a large state psychiatric hospitalJohn E Kraus, Brian B Sheitman
The Journal of Clinical Psychiatry|August 5, 2004
Neurosyphilis in newly admitted psychiatric patients: three case reportsSusan Saik, John E Kraus, Alex McDonald, et al.
The Journal of Clinical Psychiatry|January 13, 2006
Olanzapine versus risperidone in newly admitted acutely ill psychotic patientsJohn E Kraus, Brian B Sheitman, Alan Cook, et al.
Administration and Policy in Mental Health|December 7, 2007
Managing treatment resistant violent adolescents: a step forward by substituting seclusion for mechanical restraint?Thomas C Larson, Brian B Sheitman, John E Kraus, et al.
Journal of Clinical Psychopharmacology|October 2, 2003
Effects of topiramate on aggressive, self-injurious, and disruptive/destructive behaviors in the intellectually disabled: an open-label retrospective studyDavid S Janowsky, John E Kraus, Jarrett Barnhill, et al.
The Journal of Clinical Psychiatry|March 4, 2011
Meta-analysis of efficacy and treatment-emergent suicidality in adults by psychiatric indication and age subgroup following initiation of paroxetine therapy: a complete set of randomized placebo-controlled trialsDavid J Carpenter, Regan Fong, John E Kraus, et al.
Journal of the American Academy of Dermatology|January 8, 2019
Phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasisKevin Robbins, Robert Bissonnette, Tomoko Maeda-Chubachi, et al.
CNS Drugs|October 9, 2008
Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disordersDavid V Sheehan, Matthew S Keene, Michael Eaddy, et al.
Journal of the American Academy of Dermatology|December 18, 2018
A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitisJohnny Peppers, Amy S Paller, Tomoko Maeda-Chubachi, et al.
Pageof 2